SAR156497, an exquisitely selective inhibitor of Aurora kinases

Journal of Medicinal Chemistry

Volumn 58, Issue 1, 2015, Pages 362-375

  Carry, Jean Christophe ^a   Clerc, François ^a   Minoux, Hervé ^a   Schio, Laurent ^a   Mauger, Jacques ^b   Nair, Anil ^b   Parmantier, Eric ^a   Le Moigne, Ronan ^a   Delorme, Cécile ^a   Nicolas, Jean Paul ^a   Krick, Alain ^a   Abécassis, Pierre Yves ^a   Crocq Stuerga, Véronique ^a   Pouzieux, Stéphanie ^a   Delarbre, Laure ^a   Maignan, Sébastien ^a   Bertrand, Thomas ^a   Bjergarde, Kirsten ^b   Ma, Nina ^b   Lachaud, Sylvette ^a   Guizani, Houlfa ^a   Lebel, Rémi ^a   Doerflinger, Gilles ^a   Monget, Sylvie ^a   Perron, Sébastien ^a   Gasse, Francis ^a   Angouillant Boniface, Odile ^a   Filoche Rommé, Bruno ^a   Murer, Michel ^a   Gontier, Sylvie ^a   Prévost, Céline ^a   Monteiro, Marie Line ^a   Combeau, Cécile ^a   more..

^a SANOFI   (France)

^b Structure Design Informatics Sanofi ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 1 (TETRAHYDROPYRAN 2 YL) 1H BENZIMIDAZOLE; 3 [1 (TETRAHYDROPYRAN 2 YL) 1H BENZIMIDAZOL 2 YLOXY]BENZALDEHYDE; 4 [3 (4 CHLOROPHENOXY)PHENYL] 2,4,6,7,8,9 HEXAHYDROPYRAZOLO[3,4 9B]1,7 NAPHTHYRIDIN 5 ONE TRIFLUOROACETATE; 4 [5 (1H BENZIMIDAZOL 2 YLSULFANYL)FURAN 2 YL] 1,4,6,7,8,9HEXAHYDROPYRAZOLO[3,4 9B]UINOLIN 5 ONE; 9 [5 (1H BENZIMIDAZ OL 2 YLSULFANYL)FURAN 2 YL] 8 OXO 4,5,6,7,8,9 HEXAHYDRO 2H PYRROLO[3,4B]QUINOLINE 3 CARBOXYLIC ACID ETHYL ESTER TRIFLUOROACETATE; 9 [5 (1H BENZIMIDAZOL 2 YLSULFANYL)FURAN 2 YL] 8 OXO 4,5,6,7,8,9 HEXAHYDRO 2H PYRROLO[3,4B]UINOLINE 3 CARBOXYLIC ACID ETHYL ESTER; ANTINEOPLASTIC AGENT; AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; AURORA KINASE INHIBITOR; ETHYL 8 OXO 9 [3 (1H BENZIMIDAZOL 2 YLOXY)PHENYL] 4,5,6,7,8,9 HEXAHYDRO 2H PYRROLO[3,4 B]QUINOLINE 3 CARBOXYLATE; SAR 156497; UNCLASSIFIED DRUG; AURORA KINASE; BENZIMIDAZOLE DERIVATIVE; ETHYL 8-OXO-9-(3-(1H-BENZIMIDAZOL-2-YLOXY)PHENYL)-4,5,6,7,8,9-HEXAHYDRO-2H-PYRROLO(3,4-B)QUINOLINE-3-CARBOXYLATE; MOLECULAR LIBRARY; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; QUINOLONE DERIVATIVE;

ARTICLE; CELL CYCLE REGULATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; IC50; MOLECULE; PROTEIN TARGETING; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG SCREENING; FEMALE; HCT116 CELL LINE; HUMAN; METABOLISM; MOLECULAR LIBRARY; NEOPLASMS; PATHOLOGY; PHARMACOLOGY; PROTEIN TERTIARY STRUCTURE; SCID MOUSE; SF9 CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AURORA KINASE A; AURORA KINASE B; AURORA KINASE C; AURORA KINASES; BENZIMIDAZOLES; FEMALE; HCT116 CELLS; HUMANS; MICE, SCID; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; QUINOLONES; SF9 CELLS; SMALL MOLECULE LIBRARIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920771958     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501326k     Document Type: Article

References (43)

1. Goldenson, B. and Crispino, J. D. The Aurora Kinases in Cell Cycle and Leukemia. Oncogene [Online early access]. DOI: 10.1038/onc.2014.14. Published Online: March 17, 2014.
2. Kelly, K. R.; Ecsedy, J.; Devalingam, M.; Nawrocki, S. T.; Padmanabhan, S.; Giles, F. J.; Carew, J. S. Targeting Aurora Kinases in Cancer Treatment Curr. Drug Targets 2011, 12, 2067-2078
3. Portella, G.; Passaro, C.; Chieffi, P. Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer Curr. Med. Chem. 2011, 18, 482-496
4. Kollareddy, M.; Dzubak, P.; Zheleva, D.; Hajduch, M. Aurora Kinases: Structure, Functions and Their Association with Cancer Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2008, 152, 27-33
5. Pollard, J. R.; Mortimore, M. Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents J. Med. Chem. 2009, 52, 2629-2651
6. Gruneberg, U.; Neef, R.; Honda, R.; Nigg, E. A.; Barr, F. A. Relocation of Aurora B from Centromeres to the Central Spindle at the Metaphase to Anaphase Transition Requires MKlp2 J. Cell Biol. 2004, 166, 167-172
7. Lassus, H.; Staff, S.; Leminen, A.; Isola, J.; Butzow, R. Aurora-A Overexpression and Aneuploidy Predict Poor Outcome in Serous Ovarian Carcinoma Gynecol. Oncol. 2011, 120, 11-17
8. Takeshita, M.; Koga, T.; Takayama, K.; Ijichi, K.; Yano, T.; Maehara, Y.; Nakanishi, Y.; Sueishi, K. Aurora-B Overexpression Is Correlated with Aneuploidy and Poor Prognosis in Non-Small Cell Lung Cancer Lung Cancer 2013, 80, 85-90
9. Kollareddy, M.; Zheleva, D.; Dzubak, P.; Brahmkshatriya, P. S.; Lepsik, M.; Hajduch, M. Aurora Kinase Inhibitors: Progress toward the Clinic Invest. New Drugs 2012, 30, 2411-2432
10. Green, M. R.; Woolery, J. E.; Mahadevan, D. Update on Aurora Kinase Targeted Therapeutics in Oncology Expert Opin. Drug Discovery 2011, 6, 291-307
11. Görgün, G.; Hideshima, T.; Anderson, K. C. MLN-8237 Drugs Future 2010, 35, 903-908
12. Zhang, S.; Farag, S. S. ENMD-2076 Drugs Future 2011, 36, 5-15
13. How, J.; Yee, K.; Anderson, K. C. ENMD-2076 for Hematological Malignancies Expert. Opin. Invest. Drugs 2012, 21, 717-732
14. Meulenbeld, H. J.; Mathijssen, R. H. J.; Verweij, J.; de Wit, R.; de Jonge, M. J. A. Danusertib, an Aurora Kinase Inhibitor Expert. Opin. Invest. Drugs 2012, 21, 383-393
15. Wang, Y.; Serradell, N. VX-680/MK-0457 Drugs Future 2007, 32, 144-147
16. Mauger, J.; Nair, A.; Ma, N.; Bjergarde, K.; Filoche-Rommé, B.; Angouillant-Boniface, O.; Mignani, S. Preparation of 1,4-Dihydropyridine-Fused Heterocycles as Inhibitors of Aurora Kinase. Eur. Pat. Appl. EP1746097A1 20070124, 2007.
17. Carry, J.-C.; Cheve, M.; Clerc, F.; Combeau, C.; Gontier, S.; Krick, A.; Lachaud, S.; Schio, L. Preparation of Benzimidazolylpyrrole Quinoline Derivatives as Anticancer Agents. PCT Int. Appl. WO2010133794A1 20101125, 2010.
18. Arokiassamy, N.; Billot, P.; Carry, J.-C.; Clavieres, P.; Clerc, F.; Crocq-Stuerga, V.; Lachaud, S.; Lienard, P.; Menegotto, J.; Schio, L. (-)-Ethyl 8-Oxo-9-[3-[(1 H -benzimidazol-2-yl)oxy]phenyl]-4,5,6,7,8,9-hexahydro-2 H -pyrrolo[3,4- b ]quinoline-3-carboxylate, and Its Salt, Crystalline Form, Cocrystal, Processes for Preparation, Formulations, Pharmaceutical Compositions and New Use Particularly as Selective Inhibitors of Aurora Kinases for Treating Cancers. PCT Int. Appl. WO2012066486A1 20120524, 2012.
19. Sotriffer, C.; Klebe, G.; Stahl, M.; Böhm, H.-J. Docking and Scoring Functions/Virtual Screening. In Burger's Medicinal Chemistry and Drug Discovery, 6 th ed.; Abraham, D. J., Ed.; Wiley: Hoboken, NJ, 2003; pp 281-331.
20. Kong, X.; Qin, J.; Li, Z.; Vultur, A.; Tong, L.; Feng, E.; Rajan, G.; Liu, S.; Lu, J.; Liang, Z.; Zheng, M.; Zhu, W.; Jiang, H.; Herlyn, M.; Liu, H.; Marmorstein, R.; Luo, C. Development of a Novel Class of B-Raf V600E-Selective Inhibitors through Virtual Screening and Hierarchical Hit Optimization Org. Biomol. Chem. 2012, 10, 7402-7417
21. Kornev, A. P.; Haste, N. M.; Taylor, S. S.; Ten Eyck, L. F. Surface Comparison of Active and Inactive Protein Kinases Identifies a Conserved Activation Mechanism Proc.Natl. Acad. Sci. U.S.A. 2006, 103, 17783-17788
22. Martin, M. P.; Zhu, J.-Y.; Lawrence, H. R.; Pireddu, R.; Luo, Y.; Alam, R.; Ozcan, S.; Sebti, S. M.; Lawrence, N. J.; Schönbrunn, E. A Novel Mechanism by Which Small Molecule Inhibitors Induce the DFG Flip in Aurora A ACS Chem. Biol. 2012, 7, 698-706
23. Catalyst; Accelrys Software Inc.: San Diego, CA.
24. Jones, G.; Willett, P.; Glen, R. C. Molecular Recognition of Receptor Sites Using a Genetic Algorithm with a Description of Desolvation J. Mol. Biol. 1995, 245, 43-53
25. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and Validation of a Genetic Algorithm for Flexible Docking J. Mol. Biol. 1997, 267, 727-748
26. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy J. Med. Chem. 2004, 47, 1739-1749
27. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening J. Med. Chem. 2004, 47, 1750-1759
28. Molecular Operating Environment (MOE); Chemical Computing Group Inc.: Montreal, Quebec, Canada.
29. Palmieri, L.; Rastelli, G. αC Helix Displacement as a General Approach for Allosteric Modulation of Protein Kinases Drug Discovery Today 2013, 18, 407-414
30. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the "Gatekeeper Door": Exploiting the Active Kinase Conformation J. Med. Chem. 2010, 53, 2681-2694
31. Alton, G. R.; Lunney, E. A. Targeting the Unactivated Conformations of Protein Kinases for Small Molecule Drug Discovery Expert Opin. Drug Discovery 2008, 3, 595-605
32. Zhang, J.; Herman, E. H.; Knapton, A.; Chadwick, D. P.; Whitehurst, V. E.; Koerner, J. E.; Papoian, T.; Ferrans, V. J.; Sistare, F. D. SK&F 95654-Induced Acute Cardiovascular Toxicity in Sprague-Dawley Rats-Histopathologic, Electron Microscopic, and Immunohistochemical Studies Toxicol. Pathol. 2002, 30, 28-40
33. Fossa, P.; Giordanetto, F.; Menozzi, G.; Mostia, L. Structural Basis for Selective PDE 3 Inhibition: A Docking Study Quant. Struct.-Act. Relat. 2002, 21, 267-275
34. Zhou, S.; Chan, S. Y.; Goh, B. C.; Chan, E.; Duan, W.; Huang, M.; McLeod, H. L. Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs Clin. Pharmacokinet. 2005, 44, 279-304
35. Hu, Y.; Furtmann, N.; Bajorath, J. Current Compound Coverage of the Kinome J. Med. Chem. [Online early access]. DOI: 10.1021/jm5008159. Published Online: July 22, 2014.
36. Kornev, A. P.; Taylor, S. S. Defining the Conserved Internal Architecture of a Protein Kinase Biochim. Biophys. Acta, Proteins Proteomics 2010, 1804, 440-444
37. Martin, E.; Mukherjee, P. Kinase-Kernel Models: Accurate in silico Screening of 4 Million Compounds across the Entire Human Kinome J. Chem. Inf. Model. 2012, 52, 156-170
38. Bavetsias, V.; Faisal, A.; Crumpler, S.; Brown, N.; Kosmopoulou, M.; Joshi, A.; Atrash, B.; Pérez-Fuertes, Y.; Schmitt, J. A.; Boxall, K. J.; Burke, R.; Sun, C.; Avery, S.; Bush, K.; Henley, A.; Raynaud, F. I.; Workman, P.; Bayliss, R.; Linardopoulos, S.; Blagg, J. Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5- b ]pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells J. Med. Chem. 2013, 56, 9122-9135
39. Chebanov, V. A.; Saraev, V. E.; Desenko, S. M.; Chernenko, V. N.; Knyazeva, I. V.; Groth, U.; Glasnov, T. N.; Kappe, C. O. Tuning of Chemo- and Regioselectivities in Multicomponent Condensations of 5-Aminopyrazoles, Dimedone, and Aldehydes J. Org. Chem. 2008, 73, 5110-5118
40. Chebanov, V. A.; Saraev, V. E.; Desenko, S. M.; Chernenko, V. N.; Shishkina, S. V.; Shishkin, O. V.; Kobzar, K. M.; Kappe, C. O. One-Pot, Multicomponent Route to Pyrazoloquinolizinones Org. Lett. 2007, 9, 1691-1694
41. Drizin, I.; Altenbach, R. J.; Buckner, S. A.; Whiteaker, K. L.; Scott, V. E.; Darbyshire, J. F.; Jayanti, V.; Henry, R. F.; Coghlan, M. J.; Gopalakrishnan, M.; Carroll, W. A. Structure-Activity Studies for a Novel Series of Tricyclic Dihydropyridopyrazolones and Dihydropyridoisoxazolones as KATP Channel Openers Bioorg. Med. Chem. 2004, 12, 1895-1904
42. Quiroga, J.; Mejía, D.; Insuasty, B.; Abonía, R.; Nogueras, M.; Sánchez, A.; Cobo, J.; Low, J. N. Regioselective Synthesis of 4,7,8,9-Tetrahydro-2 H -pyrazolo[3,4- b ]-quinolin-5(6 H)-ones. Mechanism and Structural Analysis Tetrahedron 2001, 57, 6947-6953
43. Knudsen, S. M.; Pettersson, I.; Lau, J.; Behrens, C.; Petersen, A. K.; Lau, J.; Garibay, P. W. Condensed Thiophene Derivatives and Their Use as Cyclic GLP-1 Agonists. PCT Int. Appl. WO2006003096, 2006.